Document is current

Any future updates will be listed below

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8<sup>+</sup> T cells

Crossref DOI link: https://doi.org/10.1136/jitc-2022-006611

Published Online: 2023-06-02

Published Print: 2023-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark